Patents by Inventor Michael Mark

Michael Mark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140128604
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Matthias ECKHARDT, Michael MARK, Roland MAIER, Ralf LOTZ, Mohammad TADAYYON
  • Patent number: 8703204
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: April 22, 2014
    Assignee: Bend Research, Inc.
    Inventors: Corey Jay Bloom, Marshall David Crew, Daniel Tod Smithey, Warren Kenyon Miller, Michael Mark Morgen
  • Publication number: 20140088027
    Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor and a PPAR? agonist which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: March 28, 2011
    Publication date: March 27, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rolf Grempler, Thomas Klein, Michael Mark, Leo Seman, Leo Thomas
  • Publication number: 20140087996
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: December 4, 2013
    Publication date: March 27, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thomas KLEIN, Rolf GREMPLER, Michael MARK
  • Patent number: 8673927
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: March 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Patent number: 8664232
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: March 4, 2014
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Michael Mark, Roland Maier, Ralf R. H. Lotz, Mohammad Tadayyon
  • Publication number: 20140057901
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: February 21, 2013
    Publication date: February 27, 2014
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf LOTZ
  • Publication number: 20140038911
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: June 7, 2013
    Publication date: February 6, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli BROEDL, Rolf GREMPLER
  • Publication number: 20140038451
    Abstract: A connector includes a cable tray configured to receive and retain a cable in a stable position and couple with a top cap configured to create an electrical connection with the cable as the top cap is manipulated in a predetermined manner while coupled with the cable tray. An upper surface of the cable tray is configured to receive the cable. The cable tray also includes a finger extending beyond the first end for some distance longitudinally. The finger includes a protrusion that protrudes to some extent in a transverse direction so that a cable-accommodating gap is defined between the protrusion and the first end. The protrusion is configured to bear against the cable and retain the cable in the stable position when the cable is inserted between the protrusion and the first end (before, during and/or after an electrical connection is established).
    Type: Application
    Filed: October 7, 2013
    Publication date: February 6, 2014
    Applicant: Lowe's Companies, Inc.
    Inventors: Jean Tuck McGregor, James Michael Broughman, Allen R. Nelson, Darren Michael Mark, Laura Winfield Alexander, Donald Collins Meves
  • Publication number: 20140031301
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: October 4, 2013
    Publication date: January 30, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • Patent number: 8616905
    Abstract: A connector includes a cable tray configured to receive and retain a cable in a stable position and couple with a top cap configured to create an electrical connection with the cable as the top cap is manipulated in a predetermined manner while coupled with the cable tray. An upper surface of the cable tray is configured to receive the cable (e.g., while the cable is generally parallel with the longitudinal axis of the cable tray). The cable tray also includes a finger extending beyond the first end for some distance longitudinally. The finger includes a protrusion that protrudes to some extent in a transverse direction so that a cable-accommodating gap is defined between the protrusion and the first end. The protrusion is configured to bear against the cable and retain the cable in the stable position when the cable is inserted between the protrusion and the first end.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 31, 2013
    Assignee: Lowe's Companies, Inc.
    Inventors: Jean Tuck McGregor, James Michael Broughman, Allen R. Nelson, Darren Michael Mark, Laura Winfield Alexander, Donald Collins Meves
  • Publication number: 20130337945
    Abstract: A variable gravity training device allows a user to train skills in controlling a sports device. The training device has a stationary base, a movable support bar, and a sports device, for example, a ball, a badminton birdie, or a volley ball affixed to the end of the bar. The support bar is weighted, so that the amount of force required to move the sports device is reduced. The weighted bar also reduces the speed with which the sports device returns to its home position. The force adjustment means is adjustable, so that, with training, weights may be removed, so that the conditions governing the sports device correspond to real playing conditions.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Applicant: Variable Gravity Patents, LLC
    Inventors: Michael Marks, Steven Leen
  • Publication number: 20130335576
    Abstract: Representative implementations of devices and techniques provide adaptable settings for imaging devices and systems. Operating modes may be defined based on whether an object is detected within a preselected area. One or more parameters of emitted electromagnetic radiation may be dynamically adjusted based on the present operating mode.
    Type: Application
    Filed: June 19, 2012
    Publication date: December 19, 2013
    Inventors: Martin GOTSCHLICH, Josef PRAINSACK, Michael MARK
  • Publication number: 20130324463
    Abstract: The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 5, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas KLEIN, Michael MARK
  • Publication number: 20130315975
    Abstract: The invention relates to new keratinocytes which may be cultured in vitro and the use thereof for preparing a product which can be used to treat acute and chronic wounds, in combination with a DPP-4 inhibitor.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas KLEIN, Michael MARK
  • Publication number: 20130310398
    Abstract: Combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael MARK, Peter EICKELMANN, Gerd LUIPPOLD, Leo THOMAS
  • Publication number: 20130303462
    Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas KLEIN, Maximilian von EYNATTEN, Berthold HOCHER, Michael MARK, Yuliya SHARKOVSKA
  • Publication number: 20130303554
    Abstract: The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas KLEIN, Andreas DAIBER, Klaus DUGI, Michael MARK, Thomas MUENZEL
  • Publication number: 20130281373
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Application
    Filed: May 5, 2011
    Publication date: October 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas Klein, Rolf Grempler, Michael Mark
  • Publication number: 20130273942
    Abstract: Methods, systems, and computer program products determine, for a number of individuals having a common interest, locations relevant to that common interest. Each individual possesses a user terminal that has a location and executes a messaging application. During the course of a messaging conversation, the application transmits search parameters to a central server. The search parameters may be entered manually or determined automatically by analyzing the conversation. The server identifies clusters of locations that satisfy the search parameters in addition to satisfying geographic proximity to the participants in the conversation. The server scores the clusters, and transmits to the user terminal data relating thereto, for integrated display in the messaging application. Relevant advertising may be identified and transmitted for contemporaneous display.
    Type: Application
    Filed: April 11, 2013
    Publication date: October 17, 2013
    Applicant: Sprylogics International Corp.
    Inventors: Bhavuk Kaul, Aleksandar Zivkovic, Bradley Michael Marks, Marvin Igelman